Paying for New Drugs for New Bugs: Regulation is Only One Side of the Coin
This article was originally published in RPM Report
Executive Summary
FDA and Congress are making great strides in improving the regulatory pathway and intellectual property protection for anti-infectives. But without changes in the reimbursement process, the package of incentives may not be enough to spur innovation in the class.
You may also be interested in...
Maintaining a Sustainable Environment for Innovation: Ending the Evidence Arms Race for Regulatory and Reimbursement Decision-Making
Increasing attention on containing healthcare costs has spurred new business opportunities in data aggregation, real-time analytics, and rapid translation of data into evidence on the value of new innovation. This has become a race for more and faster evidence. But is the investment made by manufacturers, payers, and the government resulting in better evidence to aid patients and clinicians in making better decisions?